SCHEMBL4608672

SCHEMBL4608672

CCC1CC=C(c2ccc3c(c2)CCC(=O)N3)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.46
PDE3B Q13370 2/20 0.46
PDE3A Q14432 2/20 0.46
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
MMP12 P39900 1/20 0.44
RAB9A P51151 1/20 0.44
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
TBXAS1 P24557 1/20 0.43
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2B6 P20813 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896287 0.81 KIF11 (0.45) KIF11PDE3BPDE3AMAPTNPC1
SCHEMBL4596450 0.81 KIF11 (0.46) KIF11PDE3BPDE3AMAPTNPC1
SCHEMBL4894920 0.81 KIF11 (0.49) KIF11PDE3BPDE3AMAPTNPC1
SCHEMBL4596297 0.78 KIF11 (0.55) KIF11PDE3BPDE3AMAPTNPC1
SCHEMBL11199009 0.77 ESR2 (0.58) NPC1RAB9AALDH1A1BACE1ESR2
SCHEMBL11193766 0.75 ESR2 (0.56) NPC1RAB9ABACE1ESR2
SCHEMBL2234694 0.72 KIF11 (0.54) KIF11PDE3BPDE3AMAPTNPC1
Fluoride SCHEMBL9841774 0.71 ESR2 (0.49) BACE1ESR2
SCHEMBL10928954 0.71 ESR2 (0.51) NPC1RAB9AMEN1KMT2ABACE1
SCHEMBL10932411 0.70 ESR2 (0.50) NPC1RAB9AALDH1A1POLBBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176830-A1 Compounds, Compositions, and Methods ADAMS NICHOLAS D 2008-07-24 US claimed
US-20080176830-A1 Compounds, Compositions, and Methods ADAMS NICHOLAS D 2008-07-24 US disclosed
US-20080176830-A1 Compounds, Compositions, and Methods ADAMS NICHOLAS D 2008-07-24 US disclosed
EP-1874753-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-09 EP disclosed
WO-2006113432-A2 COMPOUNDS, COMPOSITIONS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176830-A1 Compounds, Compositions, and Methods ALPP, PCNA, MKI67 KIF11 562/4885PDE3B 2947/4885PDE3A 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.